

O I P E  
JAN 06 2005  
JC25

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/734,638
Date Submitted: January 6, 2005 (use as many sheets as necessary)				Filing Date	12/15/2003
				First Named Inventor	Philippe ROUANET et al.
				Group Art Unit	Unassigned
				Examiner Name	1615
				Attorney Docket Number	029488-0113
Sheet 1		of 3			

8/1/08  
(2)

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (# known)			
AMC	B1	5,904,930		Hexet AG Fischer et al.	5/18/1999	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (# known)			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
AMC	B2	J. BARRAT et al., "Effet <i>in vivo</i> de l'administration locale de progestérone sur l'activité mitotique des galactophores humains", J. Gynecol. Obstet. Biol. Reprod. 19: 269-274 1990.			
AMC	B3	Bronaugh & Maibach, "Percutaneous Absorption Drugs-Cosmetics-Mechanisms-Methodology", Marcel Dekker Inc., New York, 1999.			
AMC	B4	Philip CARTHEW et al., "Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat", Arch Toxicol (2001) 75: 375-380.			
AMC	B5	Gerard CHETRITE et al., "Effect of Promegestone, Tamoxifen, 4-Hydroxytamoxifen and ICI 164,384 on the Oestrone Sulphatase Activity of Human Breast Cancer Cells", Anticancer Research 13: 931-934 (1993).			
AMC	B6	Eric C. DIETZE et al., "Tamoxifen but Not 4-Hydroxytamoxifen Initiates Apoptosis in p53(-) Normal Human Mammary Epithelial Cells by Inducing Mitochondrial Depolarization", The Journal of Biological Chemistry Vol. 276, No. 7, Issue of February 16, 2001, pp. 5384-5394.			
AMC	B7	I.S. FENTIMAN et al., "Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial", BR. J. SURG. September 1988, Vol. 75, No. 9, pp. 845-846.			
AMC	B8	I.S. FENTIMAN et al., "Studies of tamoxifen in women with mastalgia", The British Journal of Clinical Practice, Supplement 68, Vol. 43, No. 11, November 1989, pp. 34-36.			
AMC	B9	N. GIAMBAGI et al., "IMMUNOLOGICAL DIFFERENCES BETWEEN THE ESTRADIOL-, TAMXIFEN- AND 4-HYDROXY-TAMOXIFEN-ESTROGEN RECEPTOR COMPLEXES DETECTED BY TWO MONOClonal ANTIBODIES", J. Steroid Biochem. Vol. 30, No. 1-6, pp. 213-217, 1988.			

Examiner Signature	<i>Marcel Collet</i>	Date Considered	4/21/2004
--------------------	----------------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.